Some QOL benefits for second-line Halaven in breast cancer
This article was originally published in Scrip
Executive Summary
Eisai has presented new quality of life (QOL) data from one of the main Phase III trials with its breast cancer drug Halaven (eribulin mesylate) that it will be hoping may boost the competitive position of the novel microtubule dynamics inhibitor in the earlier line treatment of metastatic disease.